Table 1.
Clinicopathological characteristics of synovial tissues obtained by surgical biopsy and ultrasound-guided biopsy
| Biopsy | Age (years) | Sex | Disease duration (years) | RF/aCCP | Disease-modifying antirheumatic drugs | Joint | Valid samples/total samples | Valid sections | Cumulative area (mm2) |
| S-SY1 | 65 | Female | 18 | +/+ | MTX | Wrist | 3/3 | 9 | 24.47 |
| S-SY2 | 44 | Female | 12 | -/- | PDN | I MTP | 3/3 | 9 | 37.72 |
| S-SY3 | 63 | Female | 14 | +/+ | MTX + HCQ | II and III MTPs | 3/3 | 9 | 44.02 |
| S-SY4 | 46 | Female | 34 | -/+ | HCQ | Wrist | 4/4 | 12 | 41.68 |
| S-SY5 | 46 | Female | 17 | -/- | LFN + PDN | Wrist | 5/5 | 15 | 60.32 |
| S-SY6 | 75 | Female | 7 | -/- | MTX + PDN | MCPs | 3/3 | 9 | 34.75 |
| S-SY7 | 78 | Female | 8 | -/- | MTX + PDN | MCPs | 3/3 | 9 | 38.68 |
| S-SY8 | 46 | Male | 2 | -/+ | MTX + PDN | MCPs | 3/3 | 9 | 22.42 |
| S-SY9 | 68 | Female | 5 | -/- | MTX + HCQ + PDN | I MTP | 3/3 | 9 | 45.01 |
| U-SY1 | 23 | Female | 5 | +/+ | CYA + PDN | II MCP | 4/8 | 12 | 16.86 |
| U-SY2 | 59 | Female | 4 | -/- | MTX + PDN | V MCP | 5/8 | 15 | 17.64 |
| U-SY3 | 64 | Female | 18 | +/+ | PDN | II PIP | 10/12 | 30 | 38.28 |
| U-SY4 | 61 | Female | 11 | -/+ | MTX + PDN | V MCP | 3/12 | 9 | 7.29 |
| U-SY5 | 69 | Male | 10 | +/+ | MTX + HCQ + PDN | II MCP | 8/12 | 24 | 20.16 |
| U-SY6 | 75 | Male | 11 | +/+ | HCQ + SLZ + PDN | V MCP | 10/12 | 29 | 28.71 |
| U-SY7 | 67 | Female | 7 | -/+ | MTX + HCQ + PDN | II MCP | 8/12 | 23 | 8.82 |
| U-SY8 | 62 | Female | 8 | -/- | MTX + PDN | II MCP | 7/12 | 20 | 8.43 |
| U-SY9 | 61 | Female | 11 | +/+ | MTX + HCQ + PDN | II MCP | 9/12 | 26 | 20.91 |
The good quality/overall number of collected sample rate and the number of valid sections obtained considering three different cutting levels are provided. The cumulative area is computed on overall sections for each patient. S-SY, surgical biopsy synovial tissue; U-SY, ultrasound-guided biopsy synovial tissue; RF/aCCP, rheumatoid factor/anticyclic citrullinated peptide antibodies; MTX, methotrexate: PDN, prednisone; HCQ, hydroxychloroquine; LFN, leflunomide; CYA, cyclosporine A; SLZ, sulfasalazine; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal.